Vusolimogene oderparepvec clinical trials
4 indexed studies · 1 currently recruiting
- Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
This study is testing a new treatment called RP1, by itself and with another medicine (Opdivo), for adults with various types of cancer (solid tumors). It aims to see how safe the treatment is and if it helps shrink tumors.
For: Solid tumorsGermany · France · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma [CERPASS]
This study is looking at a new treatment for advanced skin cancer (cutaneous squamous cell carcinoma). It's testing a drug called cemiplimab, either alone or with another treatment called Vusolimogene oderparepvec, to see how well they shrink tumours and if they are safe.
For: Cutaneous Squamous Cell CarcinomaSpain · Greece · Germany - RecruitingPHASE3
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
This study looks at a new treatment called VO with nivolumab for advanced melanoma that has grown despite earlier treatments. It compares this combination to standard treatments chosen by your doctor for people aged 12 and over.
For: Advanced MelanomaUnited States · France · Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
"neoBREASTIM": A Phase 2 Study of Atezolizumab plus RP1 oncolytic immunotherapy in the NeoAdjuvant setting of Triple-Negative Breast Cancer (TNBC)
For: Patients with early-stage Triple Negative Breast CancerFrance